Amphastar Pharmaceuticals Inc AMPH 深 滬
已收盤 02-06 16:00:00 美东时间
29.26
+0.630
+2.20%
華盛通- 最 高29.46
- 今 開28.61
- 成交量 34.38万股
- 最 低 28.61
- 昨 收 28.63
- 總市值 13.45亿
- 52周最高 32.69
- 市盈率 靜 9.55
- 換手率 0.75%
- 52周最低 20.385
- 委 比 22.20%
- 總股本 4595.22万
- 歷史最高 67.66
- 量 比 0.90
- 振 幅 2.97%
- 歷史最低 6.67
- 每 手 1
- 風險率 2.66%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Amphastar Licenses New Synthetic ACTH Drug for Inflammatory Diseases in US and Canada
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that it has entered into an exclusive license agreement (the "Agreement") with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. ("Hanxin") for the
01-12 19:21
Cheap smaller cap stocks that promise acceleration in fundamentals – BofA
BofA analysts outlined a list of inexpensive small- and mid-cap stocks with accelerating fundamentals. These are Russell 2000 (IWM) stocks that have cheap valuations along with positive revisions and ...
2025-12-20 00:57
Amphastar reports FDA approval for teriparatide injection
Amphastar Pharmaceuticals (AMPH) said that the U.S. Food and Drug Administration has approved the company's abbreviated new drug application for teriparatide injection, USP 560 mcg/2.24mL (250 mcg/mL)...
2025-12-15 19:33
Amphastar Announced FDA Approval for Teriparatide Injection
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for teriparatide injection, USP 560
2025-12-15 19:05
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
2025-12-10 10:33
Barclays Initiates Coverage On Amphastar Pharma with Equal-Weight Rating, Announces Price Target of $30
Barclays analyst Glen Santangelo initiates coverage on Amphastar Pharma (NASDAQ:AMPH) with a Equal-Weight rating and announces Price Target of $30.
2025-12-09 23:22
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
Needham Maintains Buy on Amphastar Pharma, Lowers Price Target to $34
Needham analyst Serge Belanger maintains Amphastar Pharma (NASDAQ:AMPH) with a Buy and lowers the price target from $36 to $34.
2025-11-07 18:09
Amphastar Expands BAQSIMI® Distribution in Asia
The latest announcement is out from Amphastar Pharmaceuticals ( ($AMPH) ). On O...
2025-10-25 04:45
